Genprex to Present at the 2020 LD Micro Virtual Conference
March 03 2020 - 8:17AM
Business Wire
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company developing potentially
life-changing treatments for cancer and other serious diseases,
today announced it will be presenting at the third annual LD Micro
Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will
lead the company’s presentation and will be answering questions
from investors.
To access the live presentation, please use the following link:
http://bit.ly/2PFjomt.
“We are delighted to be hosting our third virtual event in order
to showcase some of the truly unique names in micro-cap,” stated
Chris Lahiji, President of LD Micro. “There are many people and
companies who are unable to attend our live events due to any
number of reasons, so we are happy to offer an additional way for
companies to present to investors without taking a lot of time out
of their day-to-day operations. While virtual events will never
replace the experience of sitting in the same room as other humans,
it is a great format for updating the investor community and
getting increased exposure."
The conference will be held via webcast and will feature more
than 40 companies in the small/micro-cap space.
About Genprex, Inc. Genprex, Inc. is a clinical-stage
gene therapy company developing potentially life-changing
treatments for cancer and other serious diseases. Genprex’s
technologies are designed to administer disease-fighting genes to
provide new treatment options for large patient populations with
cancer and other serious diseases who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to in-license and develop drug candidates to further
its pipeline of gene therapies in order to provide novel treatment
approaches for patients with cancer and other serious diseases. The
company’s lead product candidate, Oncoprex™ immunogene therapy for
non-small cell lung cancer (NSCLC), uses the company’s unique,
proprietary platform which delivers cancer-fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. In January 2020, the FDA granted Fast
Track Designation for Oncoprex in combination with AstraZeneca’s
Tagrisso® for the treatment of NSCLC. For more information, please
visit the company’s website at www.genprex.com or follow Genprex on
Twitter, Facebook and LinkedIn.
Forward-Looking Statements Statements contained in this
press release regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to,
statements regarding the effects of Genprex’s product candidates,
alone and in combination with other therapies, on cancer and other
serious diseases, as well as Genprex’s ongoing and planned
preclinical and clinical studies and potential partnerships. Risks
that contribute to the uncertain nature of the forward-looking
statements include risks relating to the effects of the safety and
effectiveness of Genprex’s product candidates, alone and in
combination with other therapies, as well as the success of
Genprex’s ongoing and planned preclinical and clinical studies and
the success of Genprex’s efforts in concluding potential partnering
arrangements for product development and commercialization. Other
risks and uncertainties associated with Genprex and its product
candidates are described more fully under the caption “Risk
Factors” and elsewhere in Genprex’s filings and reports with the
United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Genprex undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200303005263/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024